Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
Haemonetics
NYSE:HAE Community
Create a narrative
Haemonetics
Popular
Undervalued
Overvalued
Haemonetics
WA
Analyst Price Target
Consensus Narrative from 10 Analysts
VASCADE MVP XL Device Launch Will Expand Interventional Technology Market
Key Takeaways New technology investments in plasma collection and hospital markets expected to drive short and long-term profitable growth and increase market share. Expansion in interventional and hospital products to global markets is set to boost revenue, margins, and utilization rates.
View narrative
US$110.80
FV
43.7% undervalued
intrinsic discount
7.47%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
18 days ago
author updated this narrative
Your Valuation for
HAE
Haemonetics
Your Fair Value
US$
Current Price
US$62.36
15.5% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-50m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.6b
Earnings US$153.7m
Advanced
Set as Fair Value